Aviva Systems Biology
Offering antibodies to more than 7000 different targets, many that are implicated in transcription, epigenetics and cell signalling, Aviva Systems Biology leverages a high throughput antibody production process to release over 200 new antibody products every month. These complement a portfolio that already covers most members of key protein families - including transcription factors, transcription regulators, RNA binding proteins, ion channels and cell membrane proteins – underscoring Aviva’s reputation as a leader of novel proteomic discoveries.
View all Aviva Systems Biology Products
Aviva Systems Biology Honored with Bioz Rapid Star™ Award in Antibodies Category!
Aviva Systems Biology is proud to announce that it has been selected as the 2024 Bioz Stars Award Winner in the Antibodies category. This recognition highlights Aviva's significant growth and impact in the scientific community, as evidenced by the increasing number of citations of its antibody products in peer-reviewed research publications.
"We’re honoured to receive the Bioz Rapid Star Award," said Dr. Nicole Hoffner, Product Manager at Aviva Systems Biology. "This award isn’t just a reflection of the quality of our 80,000+ antibodies, it’s a testament to the hard work and ground-breaking research of our customers. We’re proud to support the scientific community with tools they can trust, and we’re just getting started. Our R&D team is actively developing new recombinant antibodies designed to push performance even further. Stay tuned."
Recombinant antibodies engineered for consistency, delivering reproducible performance in diagnostic, therapeutic and molecular image applications
The recent surge in use of recombinant DNA technology has afforded the life science market essential advantages over non-recombinant antibody types. The technology allows consistent identification of specific antibody sequences and allows the sequences to be cloned and expressed easily and precisely.
Here are some key advantages that Aviva’s recombinant range can offer researchers:
High specificity: Recombinant antibodies are engineered to have very high specificity and selectivity for their target antigen.
Reduced batch variability and improved reproducibility: Recombinant antibodies are produced in a controlled and standardised manner, ensuring batch-to-batch consistency.
Availability for difficult targets: In cases where traditional immunisation methods fail to generate antibodies against highly conserved or difficult-to-obtain antigens, recombinant antibody generation allows access to antibodies that specifically recognise challenging antigens.
Scalability and renewable supply: Recombinant antibodies can be produced in large quantities more easily than traditional antibody production methods. This innovative platform allows for the sustainable and continuous production of the same antibodies.
Discover a selection of products for specific targets below: